AOD-9604 CERTIFICATES OF ANALYSIS 4 COAs BN-26AD05-001 Current Variant: Size: 5mg AOD-9604 4.94 mg / 5.25 mg Purity 99.211% / 99.329% BN-25AD05-001 Previous Variant: Size: 5mg BN-24AD05-002 Previous Variant: Size: 5mg BN-24AD05-002 Previous Variant: Size: 5mg Small-Batch Research Confidence Focused research supply, documented batch by batch
If your protocol requires you to store it for many months after reconstitution, a better (though more advanced) method is to aliquot itdivide the full solution into multiple smaller sterile tubes and freeze them all at once
hospitalization required Maintenance of Remission: Immunomodulators (azathioprine, 6-MP, methotrexate) for steroid-dependent or frequently-relapsing disease Biologic monotherapy or combination therapy (biologic + immunomodulator) for moderate-to-severe disease Step-up or top-down approach based on disease severity, patient risk factors, and prior therapy Biologic Therapy Targets: TNF-: Infliximab (IV), adalimumab (SC), certolizumab pegol (SC) IL-12/23: Ustekinumab (IV induction, SC maintenance) Integrin: Vedolizumab (IV) IL-23: Risankizumab (IV induction, SC maintenance) JAK inhibition: Upadacitinib (oral) Surgical Management Surgery is indicated in approximately 7080% of patients with Crohns disease over their lifetime, per StatPearls
You can return to your daily routine immediately after your appointment
Our professionals consider your age, activity level, body-fat ratio, weight loss objectives, metabolic rate, and energy levels when making this decision
CD38 antibodies have Fc-dependent immune effector mechanisms, such as complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP)
